Section Arrow
CPRX.NASDAQ
- Catalyst Pharmaceuticals
Quotes are at least 15-min delayed:2026/04/15 22:31 EDT
Regular Hours
Last
 25.85
-0.34 (-1.30%)
Day High 
26.2 
Prev. Close
26.19 
1-M High
26.4458 
Volume 
881.06K 
Bid
25.75
Ask
26.2
Day Low
25.6 
Open
26.11 
1-M Low
22.16 
Market Cap 
3.20B 
Currency 美元 
P/E 15.61 
%Yield -- 
10-SMA 25.16 
20-SMA 24.23 
50-SMA 24.25 
52-W High 26.58 
52-W Low 19.05 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
1.68/2.91
Enterprise Value
3.20B
Balance Sheet
Book Value Per Share
7.81
Cash Flow
Cash Flow Yield
0.06
Income Statement
Total Revenue
491.73M
Operating Revenue Per Share
2.85
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
IMMPImmutep Limited0.544+0.2292+72.81%-- 
LIMNLiminatus Pharma Inc0.1856+0.0058+3.23%-- 
PPCBPropanc Biopharma Inc0.1106+0.0131+13.44%0PE
ALLOAllogene Therapeutics2.17-0.11-4.82%-- 
CUECue Biopharma0.7243+0.2863+65.37%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.